Advertisement

Topics

ImmunoGen Company Profile

05:46 EST 17th December 2018 | BioPortfolio

ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The Company's product candidates arecalled tumor-activated prodrugs ("TAPs") and are based on its proprietary immunoconjugate technology platform. Unlike conventional chemotherapeutic agents, TAPs are intended to deliver potent chemotherapy specifically to a tumor. Each TAP immunoconjugate comprises a small-molecule drug which has been chemically linked to a monoclonal antibody. The small-molecule drugs are highly potent cell-killing (cytotoxic) agents, while the monoclonal antibodies identify and bind to tumor cells. An important characteristic of TAPs is that they remain inactive and nontoxic until they bind to the surface of a tumor cell, after which their full cytotoxicity is restored.

Location

128 Sidney Street
Cambridge
MA
02139
United States of America

Contact

Phone: (617) 995-2500
Fax: 617-995-2510


News Articles [52 Associated News Articles listed on BioPortfolio]

ImmunoGen CFO David Johnston Resigns, Will Depart at End of Year

David Johnston, CFO of ImmunoGen (NASDAQ: IMGN) since 2013, has resigned effective immediately, the Waltham, MA company announced Monday. In a securities filing, ImmunoGen said Johnston he will remain...

FDA fast-tracks ImmunoGen’s treatment for ovarian cancer

US Food and Drug Administration (FDA) has awarded Fast Track designation to ImmunoGen’s lead programme mirvetuximab soravtansine for patients with...Read More... The post FDA fast-tracks ImmunoGen...

FDA fast-tracks ImmunoGen's treatment-resistant ovarian cancer therapy

The FDA awarded fast-track status to ImmunoGen's mirvetuximab soravtansine, being developed to treat patients with medium to  -More- 

ImmunoGen gets FDA fast track status for mirvetuximab soravtansine to treat platinum-resistant ovarian cancer

ImmunoGen has secured fast track designation from the US Food and Drug Administration (FDA) for its lead program, mirvetuximab soravtansine.

Public offering nets $141.7mm for ImmunoGen

ImmunoGen Inc. (antibody-drug conjugates for cancer) netted $141.7mm through a public offering of 13.7mm common shares at $11. (The company originally filed to sell 12mm shares.) Proceeds will support...

Public offering nets $162.9mm for ImmunoGen

ImmunoGen Inc. (antibody-drug conjugates for cancer) netted $162.9mm through a public offering of 15.75mm common shares (including the overallotment) at $11. (The company originally filed to sell 12mm...

ImmunoGen announces study results of platinum-resistant ovarian cancer therapy at ESMO 2018 Congress

ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced initial safety and preliminary anti-tumor activity from the FORWARD II expansi...

ImmunoGen, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 31052018] Prices from USD $350

ImmunoGen, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's ImmunoGen, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investments report inc...

Drugs and Medications [0 Results]

None

PubMed Articles [25 Associated PubMed Articles listed on BioPortfolio]

HIV Env on Lockdown.

No immunogen has been found that elicits a broadly neutralizing antibody (bNAb) response sufficient for development into an HIV vaccine. In this issue of Cell Host and Microbe, Zhang et al. (2018) ra...

Structure-based immunogen design-leading the way to the new age of precision vaccines.

Vaccines have been one of the most successful interventions in global health. However, traditional vaccine development has proven insufficient to deal with pathogens that elude the immune system throu...

Development of a novel S. Typhi and Paratyphi A outer membrane vesicles based bivalent vaccine against enteric fever.

Salmonella Typhi and Salmonella Paratyphi A are the leading causative agents of enteric fever which cause morbidity and mortality worldwide. Currently, there is no combination vaccine which could prot...

Immunogenicity comparison of lactoferrin purified from Saudi Arabia camel clans milk.

Secretory lactoferrins play a crucial rolls at mucosal surfaces as not only antimicrobial molecules in primate as well as human, but as physiological protein. Its multiple functions extended to be one...

Strategies for a multi-stage neutralizing antibody-based HIV vaccine.

A critical property of a prophylactic HIV vaccine is likely to be its ability to elicit broadly neutralizing antibodies (bnAbs). BnAbs typically have multiple unusual features and are generated in a f...

Clinical Trials [26 Associated Clinical Trials listed on BioPortfolio]

Safety and Efficacy of G17DT Immunogen in the Treatment of Gastric and Gastroesophageal Cancer

This study will test whether the G17DT Immunogen, when administered in combination with chemotherapy, is an effective and safe treatment for gastric cancer.

Safety and Efficacy of G17DT Immunogen in the Treatment of Advanced Pancreatic Carcinoma

This study will test whether the G17DT Immunogen, when administered in combination with chemotherapy, is an effective and safe treatment for pancreatic cancer.

A Multicenter, Double-Blind, Phase III, Adjuvant-Controlled Study of the Effect of 10 Units of HIV-1 Immunogen (Remune) Compared to Incomplete Freund's Adjuvant (IFA) Alone Every 12 Weeks on AIDS-Free Survival in Subjects With HIV Infection and CD4 T-Lymp

To determine the effect of HIV-1 immunogen (Remune) on AIDS-free survival, defined as the time prior to development of an AIDS-defining condition or death.

A Phase I Trial To Evaluate the Safety and Immunogenicity of the UBI HIV-1MN PND Peptide Immunogen, Given by IM Injection, in Combination With the UBI Microparticulate Monovalent HIV-1 MN Branched Peptide Given Orally, in HIV-1 Uninfected Volunteers.

To evaluate safety and immunogenicity of 2 different HIV-1 peptide candidate vaccines, the UBI HIV-1 MN PND peptide immunogen and the UBI microparticulate monovalent HIV-1 MN branched pept...

Controlling Acute or Early HIV Infection With Antiretroviral Drugs, With or Without a Candidate Vaccine

The purpose of this study is to determine the role of HIV-specific CD4 T cell responses and immune responses dependent upon these CD4 responses that develop when antiretroviral drugs are s...

Companies [7 Associated Companies listed on BioPortfolio]

ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cell-killing agent...

ImmunoGen

ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The Company's product candidates arecalled tumor-activated prodrugs ("TAPs") and are based on its proprietary immunocon...

Industrial Research Limited - UK

IRL Biopharm is a highly skilled contract manufacturing business focused on developing and manufacturing novel secondary metabolites for our growing number of biotech and pharma clients around the glo...

Immunitor Corporation Co., Ltd

Immunitor Corporation Co., Ltd., is the first private biotech company formed in Thailand Technology developed by Immunitor allows to formulate any desired immunogen or antigen as an or...

Vical Incorporated

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applica...

More Information about "ImmunoGen" on BioPortfolio

We have published hundreds of ImmunoGen news stories on BioPortfolio along with dozens of ImmunoGen Clinical Trials and PubMed Articles about ImmunoGen for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ImmunoGen Companies in our database. You can also find out about relevant ImmunoGen Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers)  - Mouth cancer can develop on the lip, the tongue, the floor...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Corporate Database Quicklinks



Searches Linking to this Company Record